PURPOSE: Study of the course of possible treatment-related cognitive impairment in patients with small cell lung cancer. METHODS AND MATERIALS: Thirty-two consecutive patients with small cell lung cancer underwent successive neurologic and neuropsychologic examinations until 5 months after prophylactic cranial irradiation, and in their pretherapeutic condition were compared to matched controls. Patients with brain metastases were excluded from this study. RESULTS: Neurologic examination revealed central nervous system (CNS) abnormalities only in the 14 patients with brain metastases. In the remaining patients, neuropsychologic tests showed clear differences between the pretherapeutic performance of patients and that of matched controls (p < 0.001), but no significant deterioration either during or after therapy (0.1 < p < 0.8). CONCLUSION: The difference between the pretherapeutic performance of patients and that of matched controls may indicate disease-related cognitive impairment. Within the observation period, no adverse effects of the used therapy were found. Our observations underline the importance of a pretherapeutic assessment in neurotoxicity research.
PURPOSE: Study of the course of possible treatment-related cognitive impairment in patients with small cell lung cancer. METHODS AND MATERIALS: Thirty-two consecutive patients with small cell lung cancer underwent successive neurologic and neuropsychologic examinations until 5 months after prophylactic cranial irradiation, and in their pretherapeutic condition were compared to matched controls. Patients with brain metastases were excluded from this study. RESULTS: Neurologic examination revealed central nervous system (CNS) abnormalities only in the 14 patients with brain metastases. In the remaining patients, neuropsychologic tests showed clear differences between the pretherapeutic performance of patients and that of matched controls (p < 0.001), but no significant deterioration either during or after therapy (0.1 < p < 0.8). CONCLUSION: The difference between the pretherapeutic performance of patients and that of matched controls may indicate disease-related cognitive impairment. Within the observation period, no adverse effects of the used therapy were found. Our observations underline the importance of a pretherapeutic assessment in neurotoxicity research.
Authors: C Parageorgiou; C Dardoufas; V Kouloulias; E Ventouras; N Uzunoglu; L Vlahos; A Rambavilas; G Christodoulou Journal: J Neurooncol Date: 2000-12 Impact factor: 4.130
Authors: Aaron H Wolfson; Kyounghwa Bae; Ritsuko Komaki; Christina Meyers; Benjamin Movsas; Cecile Le Pechoux; Maria Werner-Wasik; Gregory M M Videtic; Yolanda I Garces; Hak Choy Journal: Int J Radiat Oncol Biol Phys Date: 2010-08-26 Impact factor: 7.038
Authors: Aminah Jatoi; Stephen P Kahanic; Stephen Frytak; Paul Schaefer; Robert L Foote; Jeff Sloan; Ronald C Petersen Journal: Support Care Cancer Date: 2004-10-09 Impact factor: 3.603
Authors: Marco Ronald Hassler; Katarzyna Elandt; Matthias Preusser; Johann Lehrner; Petra Binder; Karin Dieckmann; Andrea Rottenfusser; Christine Marosi Journal: J Neurooncol Date: 2009-09-10 Impact factor: 4.130
Authors: Agnes V Tallet; David Azria; Fabrice Barlesi; Jean-Philippe Spano; Antoine F Carpentier; Antony Gonçalves; Philippe Metellus Journal: Radiat Oncol Date: 2012-05-28 Impact factor: 3.481